EMA Recommends Extension of Indications for Pirtobrutinib By Ogkologos - April 24, 2025 766 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Women with Diabetes Less Likely to Opt into Cancer Screening, Despite... October 25, 2019 FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer June 27, 2025 PET Positivity After Two Cycles of ABVD Is Associated with a... November 22, 2023 Growing the Cancer Research Pipeline by Expanding Opportunities August 29, 2024 Load more HOT NEWS The Future Front Line: Pre-Med During COVID-19 EMA Recommends Granting a Conditional Marketing Authorisation for Talquetamab Tips On Staying Cool During a Heat Wave Grabbing the Perfect Gift
